NovImmune SA   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Geneva Switzerland (1998)
Status: Acquired by Swedish Orphan Biovitrum (2019) → now Advent International (2021)

Organization Overview

First Clinical Trial
2006
NCT00630643
First Marketed Drug
2018
emapalumab-lzsg (gamifant)
First NDA Approval
2018
emapalumab-lzsg (gamifant)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NovImmune SA | NOVIMMUNE S.A.